Teladoc (TDOC) Receives a Hold from Cantor Fitzgerald


In a report released today, Steven Halper from Cantor Fitzgerald reiterated a Hold rating on Teladoc (TDOC), with a price target of $135.00. The company’s shares closed last Monday at $116.86, close to its 52-week high of $125.91.

According to TipRanks.com, Halper is a 5-star analyst with an average return of 13.4% and a 62.8% success rate. Halper covers the Services sector, focusing on stocks such as Evolent Health, Tivity Health, and Hms Holdings.

Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $103.33, representing a -13.9% downside. In a report issued on February 12, Wells Fargo also downgraded the stock to Hold with a $105.00 price target.

See today’s analyst top recommended stocks >>

Based on Teladoc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $19.04 million. In comparison, last year the company had a GAAP net loss of $24.88 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002 by George Byron Brooks and is headquartered in Purchase, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts